Hyosung TNC KRX:298020KOSPI

효성티앤씨 · Korean news coverage and regulatory filings, organized.

Articles, 24h2
Articles, 7 days5
DART filings, 7 days7
Articles tracked44since Sep 11

In Q2 2026, Hyosung TNC reported revenue of ₩2.42tn, up 27.9% year on year, and operating profit of ₩189bn. Hyosung TNC (효성티앤씨) appeared in 5 Korean news articles and 7 DART filings over the past seven days. Coverage peaked on Oct 26 with 2 articles. The most common catalyst was tech & capacity (1).

Filing signals Profit +50% Revenue & profit growth Insider buying Insider selling Screener

Hyosung TNC quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩2.42tn+27.9%₩189bn
margin 7.8%
₩124bn
Q1 2026₩2.09tn+7.2%₩86.2bn
margin 4.1%
₩50.9bn
Q4 2025 derived₩1.84tn-6.8%₩44.7bn
margin 2.4%
−₩23.3bn
Q3 2025₩2.01tn+3.8%₩56.1bn
margin 2.8%
₩15.7bn
Q2 2025₩1.89tn-4.7%₩73.3bn
margin 3.9%
₩21.4bn
Q1 2025₩1.95tn+3.9%₩77.4bn
margin 4.0%
₩24.5bn
Q4 2024 derived₩1.98tn+11.9%₩42.4bn
margin 2.1%
–
Q3 2024₩1.94tn-1.7%₩67.6bn
margin 3.5%
–

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Hyosung TNC top stories 2 weeks, by number of outlets

  1. 1
    효성티앤씨, 3분기 영업익 전년比 96% 증가 … 스판덱스 업황 회복에 수익성 개선
    1 outlets · 1 articlesFirst report Oct 30 17:26 뉴데일리경제Earnings
  2. 2
    하나증권 "중국 증설 사이클 끝나가나…효성티앤씨 스판덱스 업황 회복 기대"
    1 outlets · 1 articlesFirst report Oct 19 16:28 핀포인트뉴스Capacity expansion
  3. 3
  4. 4
    [힘내라 K산업]⑤ 코펜하겐서 뉴욕까지… 효성티앤씨 '리젠 바이오' 유럽 공략
    1 outlets · 1 articlesFirst report Oct 26 08:00 아시아타임즈
  5. 5
  6. 6
    효성티앤씨 5거래일 거래대금 44% 감소
    1 outlets · 1 articlesFirst report Oct 21 22:20 비건뉴스

Latest Hyosung TNC news Korean headlines